Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caner Saygin

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Haematologica|September 11, 2025
CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemiasOlivia Arnold, Caner Saygin
Blood Reviews|January 11, 2021
Current and emerging strategies for management of myelodysplastic syndromesCaner Saygin, Hetty E Carraway
Journal of Hematology & Oncology|April 20, 2017
Emerging therapies for acute myeloid leukemiaCaner Saygin, Hetty E Carraway
Hematology. American Society of Hematology. Education Program|December 4, 2020
Therapy for lower-risk MDSHetty E Carraway, Caner Saygin
Cancers|July 24, 2021
Genetics of Myelodysplastic SyndromesCaner Saygin, Lucy A Godley
Current Medicinal Chemistry|February 11, 2015
Currently Used Biologic Agents in the Management of Behcet's SyndromeCaner Saygin, Didem Uzunaslan, Gulen Hatemi
Haematologica|December 1, 2022
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patientsCaner Saygin, Joseph Cannova, Wendy Stock, et al.
Clinical and Experimental Rheumatology|March 24, 2015
Suicidal ideation among patients with Behçet's syndromeCaner Saygin, Didem Uzunaslan, Gulen Hatemi, et al.
Blood Advances|April 27, 2021
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignanciesAnand A Patel, Kirk Cahill, Caner Saygin, et al.
Rheumatology (Oxford, England)|December 27, 2013
No appreciable decrease in fertility in Behçet's syndromeDidem Uzunaslan, Caner Saygin, Gulen Hatemi, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Haematologica|September 11, 2025
CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemiasOlivia Arnold, Caner Saygin
Blood Reviews|January 11, 2021
Current and emerging strategies for management of myelodysplastic syndromesCaner Saygin, Hetty E Carraway
Journal of Hematology & Oncology|April 20, 2017
Emerging therapies for acute myeloid leukemiaCaner Saygin, Hetty E Carraway
Hematology. American Society of Hematology. Education Program|December 4, 2020
Therapy for lower-risk MDSHetty E Carraway, Caner Saygin
Cancers|July 24, 2021
Genetics of Myelodysplastic SyndromesCaner Saygin, Lucy A Godley
Current Medicinal Chemistry|February 11, 2015
Currently Used Biologic Agents in the Management of Behcet's SyndromeCaner Saygin, Didem Uzunaslan, Gulen Hatemi
Haematologica|December 1, 2022
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patientsCaner Saygin, Joseph Cannova, Wendy Stock, et al.
Clinical and Experimental Rheumatology|March 24, 2015
Suicidal ideation among patients with Behçet's syndromeCaner Saygin, Didem Uzunaslan, Gulen Hatemi, et al.
Blood Advances|April 27, 2021
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignanciesAnand A Patel, Kirk Cahill, Caner Saygin, et al.
Rheumatology (Oxford, England)|December 27, 2013
No appreciable decrease in fertility in Behçet's syndromeDidem Uzunaslan, Caner Saygin, Gulen Hatemi, et al.
Pageof 7